# Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer

> **NCT03015740** · PHASE1,PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 42 (actual)

## Conditions studied

- Clear Cell Renal Cell Carcinoma
- Metastatic Kidney Carcinoma
- Stage III Renal Cell Cancer AJCC v7
- Stage IV Renal Cell Cancer AJCC v7

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Nivolumab
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration
- **DRUG:** Sitravatinib

## Key facts

- **NCT ID:** NCT03015740
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-23
- **Primary completion:** 2022-09-06
- **Final completion:** 2022-09-06
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2024-11-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03015740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03015740, "Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03015740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*